文献类型：期刊文献

英文题名：Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum

作者：Jiang, Chao[1];Liu, Ping[1];Zhang, Jingsheng[2];Bao, Wenjing[2];Qiu, Shaobo[1];Liang, Yan[1];Jiang, Lin[3,4]

机构：[1]Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200030, Peoples R China;[2]Liaoning Univ Tradit Chinese Med, China Affiliated Hosp, Shenyang 110032, Liaoning, Peoples R China;[3]E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Pharm, Shanghai 200237, Peoples R China;[4]E China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China

年份：2014

卷号：2014

外文期刊名：EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000332295400001)】；

基金：The authors thank Dr. Mo Shi (Shanghai Qi GMINIX Information Technology Co. Ltd.) for providing the preliminary processing of microarray data, all the doctors and nurses at the Medicine Department of Longhua Hospital Affiliated to Shanghai University of TCM and the China Affiliated Hospital of Liaoning University of TCM, and all the patients who generously agreed to participate in this study. This study was supported by Grants from the Shanghai Science and Technology Commission (no. 10JC1414500), the scientific research fund Project of TCM of the Shanghai Municipal Health Bureau (no. 2010J002B).

语种：英文

摘要：Myasthenia gravis (MG) is an autoimmune disease, of which the pathogenesis has remained unclear. At present, MG does not have any effective treatment with minor side effects. Jian Ji Ning (JJN), a traditional Chinese medicine formula consisting of 11 medicinal plants, has been used in the treatment of MG for many years. The present study aims to determine if the Chinese herbal medicine JJN could lighten the clinical symptoms of patients with MG via the regulation of differential microRNAs (miRNAs) expression in serum. JJN should be orally administered twice a day for 6 months. In the efficacy evaluation adopting the Quantitative Myasthenia Gravis Score (QMG), we found that JJN could improve the clinical symptoms of patients with MG more effectively. Besides, we found that JJN could regulate differential miRNAs expression in serum of patients with MG. Accordingly, we speculate that the effects of JJN on improving clinical symptoms and blood test indicators of patients with MG may be due to its inhibition of apoptotic pathways of some immune cells and its connection with the regulation of serum miRNAs of some patients. In conclusion, we believe that JJN has a reliable curative effect on patients with MG-induced neuropathologic changes.